小分子藥物的現在與未來
你想知道小分子藥物從發現到進入臨床的過程是如何嗎？你想知道中間需要克服哪些挑戰嗎？新一代的科技像是 AI 會如何改變藥物開發的流程？又是否可信呢？那絕對不可以錯過 2024 年會的第二個講題「小分子藥物的現在與未來」。在這個講題我們將透過對話的方式解答你的疑問。
Are you curious about the process of small molecule drugs from discovery to clinical trials? Do you want to know the challenges that need to be overcome along the way? How will new technologies like AI change the drug development process? And is it trustworthy? Then you definitely shouldn’t miss the second session at the 2024 Annual Symposium, ‘The Present and Future of Small Molecule Drugs.’ In this session, we’ll answer your questions through a conversational format.
Tzu-Hsuan (Leon) Huang
Director Discovery Immunology @ Vividion Therapeutics
Dr. Tzu-Hsuan (Leon) Huang is the Director of Immunology Discovery at Vividion Therapeutics, a Bayer AG subsidiary. He specializes in developing small molecules targeting traditionally undruggable proteins in autoimmune diseases. With extensive experience at Pfizer, Abbvie, and Amgen, Dr. Huang has led teams in creating innovative therapeutics, including small molecules aimed at cancer immunotherapy and tumor immune evasion.
Justin Ichida
Associate Professor @ USC, Co Founder @ AcuraStem
Dr. Justin K. Ichida is the John Douglas French Foundation Endowed Professor and Associate Professor at the Keck School of Medicine of USC. His research centers on neurodegenerative diseases like ALS and frontotemporal dementia. Dr. Ichida has co-founded two biotech companies to translate his small molecule discoveries into clinical treatments, reflecting his commitment to advancing therapeutic options for nervous system disorders.
Yong Jia
Director @ Norvatis
Dr. Yong Jia currently serves as the Director of the Discovery Science Department at Novartis, where he leads the in vitro pharmacology group. During his tenure at Novartis, he served as the project co-leader of the mutant-selective EGFR inhibitor program, leading it from target validation to the identification of the clinical drug candidate EGF816, which demonstrated proof of concept in humans during Phase I trials. Prior to joining Novartis, Dr. Jia was a Senior Scientist at AbbVie, where his group primarily supported biochemistry and enzymology in small molecule drug discovery.
Reserve your spot now!
Limited Early Bird Price $25, for 100+ biotech professionals and 10+ stellar speakers!
SOCAL TBA 南加州臺灣人生技協會 